Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Announces Management Changes-Form 8-K


Monday, 8 Jul 2013 08:30am EDT 

Eli Lilly And Co reported in its Form 8-K that On July 8, 2013, John Lechleiter, Ph.D., resumed his position as the Company's Chairman, President, And Chief Executive Officer. As previously announced, Dr. Lechleiter had taken a medical leave of absence beginning on May 6, 2013. Derica W. Rice, who served as acting Chief Executive Officer during Dr. Lechleiter's absence, will resume his position as executive vice president, Global Services and Chief Financial Officer. Ellen R. Marram, who served as interim chairperson of the Board of Directors, will resume her position as the board's lead independent director. 

Company Quote

58.857
1.065 +1.84%
19 Dec 2014